Licensing deals broaden horizons for Boryung's fimasartan
This article was originally published in Scrip
Executive Summary
South Korea's Boryung Pharma has struck the first international licensing deals for its angiotensin II antagonist antihypertensive Kanarb (fimasartan), opening the way to launches in a number of emerging markets.